Data sources: MEDLINE, PsycLIT, and Biological Abstracts were searched for a previous review initially to 1998. The present review extended this search to studies published to December 2001. Bibliographies were hand searched and researchers contacted for unpublished data.
Study selection and analysis: Only those studies published in peer reviewed English language journals were considered for inclusion. Inclusion criteria: age .18 years; diagnosed with schizophrenia (according to either Feighner, DSM-IIIR, DSM-IV, ICD-9, or ICD-10 diagnostic criteria), and had whole brain weight determined either at the time of autopsy or after formalin fixation. Participants were excluded if they: had known brain abnormalities (such as infarcts or tumours) or a history of conditions known or suspected to affect brain weight (such as neurodegenerative disorders, alcohol or substance addiction, head injury, epilepsy, or leucotomy). Analysis: results were analysed by multilevel modelling to account for known physiological influences on brain weight, such as participant's age and sex.
Outcomes: Brain weight.
MAIN RESULTS
Brain weight is significantly reduced in people with schizophrenia (n = 540) compared with control subjects (n = 794); the weighted mean difference being 24 g, 95% CI 1 to 47; p = 0.04 (approximately 1 ounce).
CONCLUSIONS
Consistent with MRI volumetric findings, brain weight is slightly but significantly reduced in people with schizophrenia. Commentary F or some time there have been suspicions that brain weight is reduced consistent with the structural change suggested by the ventricular enlargement documented in radiological studies, but the findings have been variable between postmortem samples. Harrison et al have now clearly established that the effect is real (2% of brain weight, p = 0.04) and that it applies approximately equally to males and females.
What is the meaning of the finding? As Harrison et al argue the result ''encourages a continuing search for the histological and molecular correlates of schizophrenia'', but it also sets limits on what can be expected from such a search. There has been recent interest in the question of what component of the disease deteriorates. Some patients get worse with time and some of these never experience a ''restitutio ad integrum'' (complete recovery). If a structural correlate were identified this finding would have clinical and potential therapeutic significance. But if the implication is that there is tissue loss this must be small-smaller than suggested by the interpretations of some imaging studies.
The alternative to tissue loss is that it did not develop. If schizophrenia is a ''neurodevelopmental disorder'' what is it about development that arrests? An interesting finding is that the relation between brain weight and age of onset is negative-that is, earlier onsets are associated with greater brain weight, and there is no relation with duration of illness. This suggests that some limit of brain growth has been reached and that it occurs earlier in the earlier onset cases. I would like to think that this limit has something to do with the asymmetry (the ''torque'') that is characteristic of the human cerebral cortex. 1 Perhaps myelination of transcallosal pathways sets a limit on relative cortical growth in the two hemispheres. I do not see it clearly but perhaps some such interaction might explain both the characteristic age of onset and the apparent arrest of cortical growth.
Tim Crow, MB BS PhD DPM FRCP FRCPsych POWIC, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
